SEC Form 4 · accession 0000899243-16-014515
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Scientific Officer
Period of report
Feb 24, 2016
Accepted (ET)
Feb 26, 2016 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $11.46 | Feb 24, 2016 | A | 75,000 | A | — | Feb 24, 2026 | Ordinary Shares | 75,000 | 75,000 | D |
Explanation of responses
- F1Options to buy 75,000 ordinary shares will vest and become exercisable in equal installments on each of February 24, 2017, 2018, 2019 and 2020, subject to Mr. Kirson's continued employment through such dates.